Abstract
Summary
Relationship of renal antimin-eralocorticoid effects with spironolactone and plasma levels of its δ6-metabolite, aldadiene, was investigated in adrenalectomized rats and in intact dogs treated with DCA. In comparative tests, spironolactone and aldadiene both given orally produced equal plasma levels of aldadiene, but unequal mineralocorti-coid-blocking effects. Potency ratios of approximately 3/1 and 5/1 were found for renal properties of spironolactone/aldadiene in rats and dogs, respectively. Interpretation of these data indicate that blocking activity of spironolactone is only partly accounted for by plasma titers of aldadiene.
Get full access to this article
View all access options for this article.